From cannabis to cannabinergics: New therapeutic opportunities

Pharmacology and Therapeutics

Volumn 95, Issue 2, 2002, Pages 103-117

  Goutopoulos, Andreas ^a   Makriyannis, Alexandros ^b  

^a Serono Repro Biology Institute   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

Anandamide; Cannabimimetics; Cannabinergics; Cannabinoid receptors; CB1; Therapeutics

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 3 (2 IODO 5 NITROBENZOYL) 1 (1 METHYL 2 PIPERIDINYLMETHYL)INDOLE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 [4 (1,1 DIMETHYLHEPTYL) 2,6 DIMETHOXYPHENYL] 6,6 DIMETHYLBICYCLO[3.1.1]HEPT 2 EN 2 YLMETHANOL; 5 (1,1 DIMETHYLHEPTYL) 2 (3 HYDROXY 7 HYDROXYMETHYLDECAHYDRO 1 NAPHTHYL)PHENOL; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; AM 1116; AM 374; AM 919; AMG 3; AMIDASE; ANANDAMIDE; ARACHIDONYL TRIFLUOROMETHYL KETONE; ARACHIDONYLETHANOLAMIDE AMIDOHYDROLASE; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABIS; DRONABINOL; HEXADECYLSULFONYL FLUORIDE; LIGAND; METHANANDAMIDE; N (4 HYDROXYPHENYL)ARACHIDONAMIDE; NABILONE; O 1064; RECEPTOR PROTEIN; RIMONABANT; UNCLASSIFIED DRUG;

ANALGESIA; APPETITE; ARTICLE; CELL MEMBRANE; DRUG ACTIVITY; DRUG BINDING SITE; DRUG INHIBITION; DRUG METABOLISM; DRUG STRUCTURE; DRUG TRANSPORT; ENZYME ACTIVITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MOLECULAR PROBE; MOTOR DYSFUNCTION; NONHUMAN; PAIN; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; VASODILATATION;

EID: 0036669789     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7258(02)00250-4     Document Type: Review

References (117)

1. Abadji V., Lin S.Y., Taha G., Griffin G., Stevenson L.A., Pertwee R.G., Makriyannis A. (R)-Methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. J Med Chem. 37:1994;1889-1893.
2. Aceto M.D., Scates S.M., Razdan R.K., Martin B.R. Anandamide, an endogenous cannabinoid has a very low physical dependence potential. J Pharmacol Exp Ther. 287:1998;598-605.
3. Arnone M., Maruani J., Chaperon F., Thiébot M.-H., Poncelet M., Soubrié P., Le Fur G. Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology. 132:1997;104-106.
4. Baker D., Pryce G., Croxford J.L. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature. 404:2000;84-87.
5. Baker D., Pryce G., Croxford J.L., Brown P., Pertwee R.G., Makriyannis A., Khanolkar A., Layward L., Fezza F., Bisogno T., Di Marzo V. Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J. 15:2001;300-302.
6. Bell M.R., D'Ambra T.E., Kumar V., Eissentat M.A., Herrmann J.L., Wetzel J.R., Rosi D., Philion R.E., Daum S.J., Hlasta D.J., Kulling R.K., Ackerman J.H., Haubrich D.R., Luttinger D.A., Baixman E.R., Miller M.S., Ward S.J. Antinociceptive (aminoalkyl)indoles. J Med Chem. 34:1991;1099-1110.
7. Beltramo M., Stella N., Calignano A., Lin S., Makriyannis A., Piomelli D. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science. 277:1997;1094-1097.
8. Boger D.L., Sato H., Lerner A.E., Hedrick M.P., Fesik R.A., Miyauchi H., Wilkie G.D., Austin B.J., Patricelli M.P., Cravatt B.F. Exceptionally potent inhibitors of fatty acid amide hydrolase: the enzyme responsible for degradation of endogenous oleamide and anandamide. Proc Natl Acad Sci USA. 97:2000;5044-5049.
9. Bouabula M.B., Bourrier B., Rinaldi-Carmona M., Shire D., LeFur G., Casellas P. Stimulation of cannabinoid receptor CB1 induces krox-24 expression in human astrocytoma cells. J Biol Chem. 270:1995;13973-13980.
10. Bouabula M., Poinot-Chazel C., Bourrie B., Canat X., Rinaldi-Carmona M., LeFur G., Casellas P. Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. Biochem J. 312:1995;637-641.
11. Breivogel C.S., Childers S.R. The functional neuroanatomy of brain cannabinoid receptors. Neurobiol Dis. 5:1998;417-431.
12. Brotchie J.M. Adjuncts to dopamine replacement, a pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease. Mot Disord. 13:1998;871-876.
13. Cabral G.A. Marijuana and the immune system. Nahas G.G., Sutin K.M., Harvey D.J., Agurell S. Marijuana and Medicine. 1999;317-325 Humana Press, Totowa.
14. Cabral G.A., Vasquez R. Marijuana decreases macrophage antiviral and antitumor activities. Adv Biosci. 80:1991;93-105.
15. Cadas H., Gaillet S., Beltramo M., Venance L., Piomelli D. Biosynthesis of an endogenous cannabinoid precursor in neurons and its control by calcium and cAMP. J Neurosci. 16:1996;3934-3942.
16. Cadas H., di Tomaso E., Piomelli D. Occurrence and biosynthesis of endogenous cannabinoid precursor, N-arachidonyl phosphatidylethanolamine, in rat brain. J Neurosci. 17:1997;1226-1242.
17. Calignano A., LaRana G., Giuffrida A., Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature. 394:1998;277-281.
18. Calignano A., Katona I., Desarnaud F., Giuffrida A., LaRana G., Mackie K., Freund T.F., Piomelli D. Bidirectional control of airway responsiveness by endogenous cannabinoids. Nature. 408:2000;96-101.
19. Chin C.N., Lucas-Lenard J., Abadji V., Kendall D.A. Ligand binding and modulation of cyclic AMP levels depend on the chemical nature of residue 192 of the human cannabinoid receptor 1. J Neurochem. 70:1998;366-373.
20. Christie M.J., Vaughan C.W. Cannabinoids act backwards. Nature. 410:2001;527-530.
21. Consroe P. Brain cannabinoid systems as targets for the therapy of neurological disorders. Neurobiol Dis. 5:1998;534-551.
22. D'Ambra T.E., Estep K.G., Bell M.R., Eissenstat M.A., Josef K.A., Ward S.J., Haycock D.A., Balzman E.R., Casiano F.M., Belgin N.C. Conformationally restricted analogues of pravadoline: nanomolar potent, enanatioselective, (aminoalkyl)indole agonists of the cannabinoid receptor. J Med Chem. 35:1992;124-135.
23. Deadwyler S., Hampson R.E., Childers S.R. Functional significance of cannabinoid receptors in brain. Pertwee R.G. Cannabinoid Receptors. 1995;206-227 Academic Press, London, San Diego.
24. Desarnaud F., Cadas H., Piomelli D. Anandamide amidohydrolase activity in rat brain microsomes. J Biol Chem. 270:1995;6030-6035.
25. Deutsch D., Chin S.A. Enzymatic synthesis and degradation of ananadmide, a cannabinoid receptor agonist. Biochem Pharmacol. 46:1993;791-796.
26. Deutsch D.G., Makriyannis A. Inhibitors of anandamide breakdown. NIDA Res Monogr. 173:1997;65-84.
27. Deutsch D.G., Lin S., Hill W.A.G., Morse K.L., Salehani D., Arreaza G., Omeir R.L., Makriyannis A. Fatty acid sulfonylfluorides inhibit anandamide metabolism and bind to the cannabinoid receptor. Biochem Biophys Res Commun. 231:1997;217-221.
28. Devane W., Dysarz F.A. III, Johnson M.R., Melvin L.S., Howlett A.C. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol. 34:1988;605-613.
29. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptors. Science. 258:1992;1946-1949.
30. Di Marzo V. 2-Arachidonyl-glycerol as an endocannabinoid: limelight for a formerly neglected metabolite. Biochemistry (Moscow). 63:1998;13-21.
31. Di Marzo V., Bisogno T., De Petrocellis L., Melck D., Martin B.R. Cannabimimetic fatty acid derivatives: anandamide family and other 'endocannabinoids'. Curr Med Chem. 6:1999;721-744.
32. Di Marzo V., Bisogno T., De Petrocellis L., Melck D., Orlando P., Wagner J.A., Kunos G. Biosynthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in circulating and tumoral macrophages. Eur J Biochem. 264:1999;258-267.
33. Di Marzo V., Goparaju S.K., Wang L., Liu J., Batkai S., Jarai Z., Fezza F., Miura G.I., Palmiter R.D., Sugiura T., Kunos G. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature. 410:2001;822-825.
34. Drake D.J., Tius M., Jensen S., Busch-Petersen J., Kawakami J.K., Fernandez-Garcia M.C., Fan P., Makriyannis A. Classical/nonclassical hybrid cannabinoids: southern aliphatic chain-functionalized C-6β methyl, ethyl and propyl analogues. J Med Chem. 41:1998;3596-3608.
35. Felder C.C., Joyce K.E., Briley E.M., Mansouri J., Mackie K., Blond O., Lai Y., Ma A.L., Mitchell R.L. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol. 48:1995;443-449.
36. Gallily R., Breuer A., Mechoulam R. 2-Arachidonylglycerol, an endogenous cannabinoid, inhibits tumor necrosis factor-α production in murine macrophages, and in mice. Eur J Pharmacol. 406:2000;R5-R7.
37. Gardner E.L., Vorel R. Cannabinoid transmission and reward-related events. Neurobiol Dis. 5:1998;501-533.
38. Gatley S.J., Lan R., Volkow N.D., Papas N., King P., Wong C.T., Gifford A.N., Pyatt B., Dewey S.L., Makriyannis A. Imaging of the brain marijuana receptor - development of a radioligand that binds to cannabinoid CB1 receptors in vivo. J Neurochem. 70:1998;417-423.
39. Gerard C.M., Molerau C., Vassart G., Parmentier M. Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochem J. 279:1991;129-134.
40. Giuffrida A., Parsons L.H., Kerr T.M., Rodriguez de Fonseca F., Navarro M., Piomelli D. Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci. 2:1999;358-363.
41. Glass M., Faull R.L.M., Dregnow M. Loss of cannabinoid receptors in the substantia nigra in Huntington's disease. Neuroscience. 56:1993;523-527.
42. Goparaju S.K., Ueda N., Taniguchi K., Yamamoto S. Enzymes of porcine brain hydrolyzing 2-arachidonoylglycerol, an endogenous ligand of cannabinoid receptors. Biochem Pharmacol. 57:1999;417-423.
43. Goutopoulos A., Fan P., Khanolkar A.D., Xie X.Q., Lin S.Y., Makriyannis A. Stereochemical selectivity of methanandamides for the CB1 and CB2 cannabinoid receptors and their metabolic stability. Bioorg Med Chem. 9:2001;1673-1684.
44. Green K. Marijuana and intraocular pressure. Nahas G.G., Sutin K.M., Harvey D.J., Agurell S. Marijuana and Medicine. 1999;581-589 Humana Press, Totowa.
45. Hampson R.E., Deadwyler S.A. Role of cannabinoid receptors in memory storage. Neurobiol Dis. 5:1998;474-482.
46. Hampson R.E., Deadwyler S.A. Cannabinoids, hippocampal function and memory. Life Sci. 65:1999;715-723.
47. Hanus L., Gopher A., Almog S., Mechoulam R. Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. J Med Chem. 36:1993;3032-3034.
48. 2, a peripheral cannabinoid receptor. Proc Natl Acad Sci USA. 25:1999;14228-14233.
49. Herkenham M., Lynn A.B., Little M.D., Johnson M.R., Melvin L.S., DeCosta B.R., Rice K.C. Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA. 87:1990;1932-1936.
50. Hillard C.J., Cambell W.B. Biochemistry and pharmacology of arachidonylethanolamide, a putative endogenous cannabinoid. J Lipid Res. 38:1997;2383-2398.
51. Houston D., Howlett A.C. Differential receptor-G-protein coupling evoked by dissimilar cannabinoid receptor agonists. Cell Signal. 10:1998;667-674.
52. Howlett A.C. The CB1 cannabinoid receptor in the brain. Neurob Dis. 5:1998;405-416.
53. 1 cannabinoid receptors using receptor peptide fragments and site-directed mutagenesis. Mol Pharmacol. 53:1998;504-510.
54. 1 receptor ligands. Life Sci. 65:1999;617-625.
55. Huffman J.W., Dai D., Martin B.R., Compton D.R. Design, synthesis and pharmacology of cannabimimetic indoles. Bioorg Med Chem Lett. 4:1994;563-566.
56. Huffman J.W., Yu S., Showalter V., Abood M.E., Wiley J.L., Compton D.R., Martin B.R., Bramblett R.D., Reggio P.H. Synthesis and pharmacology of a very potent cannabinoid lacking a phenolic hydroxyl with high affinity for the CB2 receptor. J Med Chem. 39:1996;3875-3877.
57. Járai Z., Wagner J., Varga K., Lake K.D., Compton D.R., Martin B.R., Zimmer A.M., Bonner T.I., Buckley N.E., Mezey E., Rajdan R.K., Zimmer A., Kunos G. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc Natl Acad Sci USA. 96:1999;14136-14141.
58. Johnson M.R., Melvin L.S. The discovery of nonclassical cannabinoid analgesics. Mechoulam R. Cannabinoids as Therapeutic Agents. 1986;121-145 CRC Press, Boca Raton.
59. Kaminski N.E., Koh W.S., Yang K.H., Lee M., Kessler F.K. Suppression of the humoral immune response by cannabinoids is partially mediated through inhibition of adenylate cyclase by a pertussis toxin-sensitive G-protein coupled mechanism. Biochem Pharmacol. 48:1994;1899-1908.
60. Khanolkar A.D., Palmer S.L., Makriyannis A. Molecular probes for the cannabinoid receptors. Chem Phys Lipids. 108:2000;37-52.
61. Kirkham T.C., Williams M. Synergistic effects of opioid and cannabinoid antagonists on food uptake. Psychopharmacology (Berlin). 153:2001;267-270.
62. Kreitzer A.C., Regehr W.G. Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells. Neuron. 29:2001;717-727.
63. Laine K., Jarvinen T., Savinainen J., Laitinen J.T., Pate D.W., Jarvinen K. Effects of topical anandamide-transport inhibitors, AM404 and olvanil, on intraocular pressure in normotensive rabbits. Pharm Res. 18:2001;494-499.
64. Lang W., Qin C., Lin C., Khanolkar A.D., Goutopoulos A., Fan P., Abouzid K., Meng Z., Biegel D., Makriyannis A. Substrate specificity and stereoselectivity of rat brain microsomal anandamide amidohydrolase. J Med Chem. 42:1999;896-902.
65. Levitt M. Cannabinoids as antiemetics in cancer chemotherapy. Mechoulam R. Cannabinoids as Therapeutic Agents. 1986;71-83 CRC Press, Boca Raton.
66. Lichtman A.H. SR 141716A enhances spatial memory as assessed in a radial-arm maze task in rats. Eur J Pharmacol. 404:2000;175-179.
67. Little P.J., Compton D.R., Johnson M.R., Melvin L.S., Martin B.R. Pharmacology and stereoselectivity of structurally novel cannabinoids in mice. J Pharmacol Exp Ther. 247:1988;1046-1051.
68. Maccarone M., Valensise H., Bari M., Lazzarin N., Romanini C., Finazzi-Agrò A. Relation between decreased anandamide hydrolase concentrations in human lymphocytes and miscarriage. Lancet. 355:2000;1326-1329.
69. Mackie K., Hille B. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc Natl Acad Sci USA. 89:1992;3825-3829.
70. Makriyannis A., Rapaka R.S. The molecular basis of cannabinoid activity. Life Sci. 24:1990;2173-2184.
71. 9-THC in the membrane bilayer. Rapaka R.S., Makriyannis A. Structure-Activity Relationships of Cannabinoids. National Institute on Drug Abuse Research Monograph. Vol. 79:1987;123-133 US Department of Health and Human Services, Rockville.
72. 2 cannabinoid receptor-mediated peripheral antinociception. Pain. 93:2001;239-245.
73. Malfait A.M., Gallily R., Sumarinawalla P.F., Malik A.S., Andreakos E., Mechoulam R., Feldmann M. The psychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci USA. 97:2000;9561-9566.
74. Martin B., Lichtman A.H. Cannabinoid transmission and pain perception. Neurobiol Dis. 5:1998;447-461.
75. Martin B.R., Mechoulam R., Razdan R.K. Discovery and characterization of endogenous cannabinoids. Life Sci. 65:1999;573-595.
76. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 346:1990;561-564.
77. Mechoulam R., Feigenbaum E. The unpaved road to the endogenous brain cannabinoid ligands, the anandamides. Pertwee R.G. Cannabinoid Receptors. 1995;233-258 Academic Press, London, San Diego.
78. Mechoulam R., Gaoni Y. Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc. 86:1967;1646-1647.
79. Mechoulam R., Ben-Shabat S., Hanus L., Ligumsky M., Kaminski N.E., Schatz A.R., Gopher A., Almog S., Martin B., Compton D.R., Pertwee R.G., Griffin G., Bayewitch M., Barg J., Vogel Z. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol. 50:1995;83-90.
80. Mechoulam R., Devane W.A., Glaser R. Cannabinoid geometry and biological activity. Nahas G.G., Sutin K.M., Harvey D.J., Agurell S. Marijuana and Medicine. 1999;65-90 Humana Press, Totowa.
81. 1 mice. J Gen Virol. 66:1985;2539-2549.
82. Muller-Vahl K.R., Kolbe H., Schneider U., Emrich H.M. Cannabinoids: possible role in the patho-physiology and therapy of Gilles de la Tourette syndrome. Acta Psychiatr Scand. 98:1998;502-506.
83. Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 365:1993;61-65.
84. Murphy L.L., Munoz R.M., Adrian B.A., Villnua M.A. Function of cannabinoid receptors in the neuroendocrine regulation of hormone secretion. Neurobiol Dis. 5:1998;432-446.
85. Nagayama T., Sinor A.D., Simon R.P., Chen J., Graham S.H., Jin K., Greenberg D.A. Cannabinoids and neuroprotection in global and focal cerebral ischemia. J Neurosci. 18:1999;2987-2995.
86. Nahas G.G., Sutin K.M., Harvey D.J., Agurell S. Marijuana and Medicine. 1999;Humana Press, Totowa.
87. Nye J.S., Voglmaier S., Martenson R.E., Snyder S.H. Myelin basic protein is an endogenous inhibitor of the high affinity cannabinoid binding site in brain. J Neurochem. 50:1988;1170-1178.
88. Ohno-Shosaku T., Maejima T., Kano M. Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. Neuron. 29:2001;729-738.
89. 8-tetrahydrocannabinols. J Med Chem. 41:1998;1195-1200.
90. Paria B.C., Dey S.K. Ligand-receptor signaling with endocannabinoids in preimplantation embryo development and implantation. Chem Phys Lipids. 108:2000;211-220.
91. Paria B.C., Das S.K., Dey S.K. The preimplantation embryo is a target for cannabinoid ligand-receptor signaling. Proc Natl Acad Sci USA. 92:1995;9460-9464.
92. Paton W.D.M. Pharmacology of marijuana. Annu Rev Pharmacol. 15:1975;191-220.
93. Pertwee R.G. Pharmacological, physiological and clinical implications of the discovery of cannabinoid receptors. Pertwee R.G. Cannabinoid Receptors. 1995;69-83 Academic Press, London, San Diego.
94. Pertwee R.G. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther. 74:1997;129-180.
95. Pertwee R.G. Cannabinoid receptor ligands: clinical and neuropharmacological considerations, relevant to future drug discovery and development. Expert Opin Invest Drugs. 9:2000;1-19.
96. Pertwee R.G., Griffin G., Hanus L., Mechoulam R. Effects of two endogenous fatty acid ethanolamides on mouse vasa deferentia. Eur J Pharmacol. 259:1994;115-120.
97. Pertwee R.G., Fernardo S.R., Griffin G., Abadji V., Makriyannis A. Effect of phenylmethylsulphonylfluoride on the potency of anandamide as an inhibitor of electrically evoked contractions in two isolated tissue preparations. Eur J Pharmacol. 272:1995;73-78.
98. Pertwee R.G., Griffin G., Fernando S.R., Li X., Hill A., Makriyannis A. AM630, a competitive cannabinoid receptor antagonist. Life Sci. 56:1995;1949-1955.
99. Piomelli D., Beltramo M., Giuffrida A., Stella N. Endogenous cannabinoid signaling. Neurobiol Dis. 5:1998;462-473.
100. Piomelli D., Beltramo M., Glasnapp S., Lin S.Y., Goutopoulos A., Xie X.Q., Makriyannis A. Structural determinants for recognition and translocation by the anandamide transporter. Proc Natl Acad Sci USA. 10:1999;5802-5807.
101. Razdan R.K. Structure-activity relationships in cannabinoids. Pharmacol Rev. 38:1986;75-134.
102. Rinaldi-Carmona M., Bath F., Heaulme M., Shire D., Calandra B., Congy C., Martinez S., Maruani J., Neliat G., Caput D., Ferrara P., Soubrie P., Breliere J.C., Lefur G. SR14176A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 350:1994;240-244.
103. Sañudo-Peña M.C., Tsou K., Walker M. Motor actions of cannabinoids in the basal ganglia output nuclei. Life Sci. 65:1999;703-713.
104. Schmid P., Paria B.C., Krebsbach R., Schmid H., Dey S.K. Changes in anandamide levels in mouse uterus are associated with uterine receptivity for embryo implantation. Proc Natl Acad Sci USA. 94:1997;4188-4192.
105. Schuel H., Chang M.C., Burkman L.J., Picone R., Makriyannis A., Zimmerman A.M., Zimmerman S. Cannabinoid receptors in sperm. Nahas G.G., Sutin K.M., Harvey D.J., Agurell S. Marijuana and Medicine. 1999;317-325 Humana Press, Totowa.
106. Shire D.C., Carillon C., Kaghad M., Calandra B., Rinaldi-Carmona M., Le Fur G., Caput D., Ferrara P. An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing. J Biol Chem. 270:1995;3726-3731.
107. 9-tetrahydrocannabinol. J Leukoc Biol. 50:1991;423-426.
108. Stella N., Schweitzer P., Piomelli D. A second endogenous cannabinoid that modulates long-term potentiation. Nature. 388:1997;773-778.
109. Vachon L., Fitzerald M.X., Solliday N.H., Gould I.A., Gaensler E.A. Single-dose effect of marijuana smoke: bronchial dynamics and respiratory-center sensitivity in normal subjects. N Engl J Med. 288:1973;985-989.
110. 9-THC on the spatial reference and working memory in mice. Psychopharmacology. 157:2001;142-150.
111. Waksman Y., Olson S.M., Carlisle S.J., Cabral G.A. The central cannabinoid receptor (CB1) mediates inhibition of nitric oxide production by rat microglial cells. J Pharmacol Exp Ther. 288:1999;1357-1366.
112. Walker J.M., Hohmann G., Martin W.J., Strangman N.M. The neurobiology of cannabinoid analgesia. Life Sci. 65:1999;665-673.
113. Williams M., Kirkham T.C. Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors. Psychopharmacology (Berlin). 153:1999;267-270.
114. Wilson R.I., Nicoll R.A. Endogenous cannabinoids mediate retrograde signaling at hippocampal synapses. Nature. 410:2001;588-592.
115. Xie X.-Q., Eissentat M., Makriyannis A. Common cannabimimetic pharmacophoric requirements between aminoalkylindoles and classical cannabinoids. Life Sci. 56:1995;1963-1970.
116. Yamada K., Rice K.C., Flippen-Anderson J.L., Eissenstat M.A., Ward S.J., Johnson M.R., Howlett A.C. (Aminoalkyl)indole isothiocyanates as potential electrophylic affinity ligands for the brain cannabinoid receptor. J Med Chem. 39:1996;1967-1974.
117. Zimmerman M.A., Zimmerman S., Raj A.Y. Effects of cannabinoids on spermatogenesis in mice. Nahas G.G., Sutin K.M., Harvey D.J., Agurell S. Marijuana and Medicine. 1999;347-358 Humana Press, Totowa.